David Hoffman studied biology as an undergraduate and completed a PhD in molecular, developmental, and developmental biology at the University of Colorado, Boulder. He completed postdoctoral work with Larry Gold (CU, Boulder), Jean-Jacques Toulme (INSERM, U. 386, Bordeaux), Alan Zahler (University of California, Santa Cruz), and Cassie Conley (NASA-Ames Research Center) before attending Cornell Law School. Dr. Hoffman spent six years in private practice with Finnegan, Henderson, Farabow, Garrett and Dunner, LLP, and Morrison and Forester, LLP, working on patent infringement litigation matters (district and appellate courts), patent application drafting and prosecution, due diligence and strategic patent portfolio development. He then left private practice to become in-house corporate patent counsel, first with Bavarian Nordic, Inc., and most recently with Genomic Health, Inc. At Bavarian Nordic, he managed all US patent prosecution, as well as a complex in-license from and a CRADA with the National Cancer Institute covering research and clinical development of various immunotherapies for the treatment cancer, including lead product PROSTVAC (currently in a Phase III trial). At Genomic Health, he was the lead patent attorney, but also worked with the contracts team to negotiate and manage a range of collaboration agreements governing ongoing work on the clinical validation of prognostic products aimed at helping breast, colon, and prostate cancer patients make more informed treatment decisions.